Table 1.
Possible treatments directly targeting WAT and/or BAT in obesity and type 2 diabetes
| Drug | Effect | Mechanism of action | Target organ | Class |
|---|---|---|---|---|
| BMP7 (OP-1TM) |
BAT activation |
Developmental regulator |
BAT |
Cytokine |
| BMP8B |
BAT activation |
Developmental regulator |
BAT, CNS |
|
| Sildenafil, vardenafil |
WAT (trans-) differentiation, (BAT activation) |
PDE5 inhibition |
WAT, (BAT) |
Enzyme inhibitor |
| Amrinone |
WAT lipolysis, (WAT transdifferentiation, BAT activation) |
PDE3 inhibition |
WAT, (BAT) |
|
| GC-1, KB-141 |
BAT activation, (WAT transdifferentiation) |
Thyroid hormone mimetics |
BAT |
Hormone |
| T3 |
BAT activation, (WAT transdifferentiation) |
Thyroid hormone |
BAT, CNS |
|
| BRL-26830, L-796568, N-5984 |
BAT activation, WAT transdifferentiation, lipolysis |
selective β3-AR agonist |
BAT, WAT |
Receptor agonist |
| Bile acids (endogenous ligands) |
BAT activation |
TGR5 receptor agonist |
BAT |
|
| ANP, BNP (endogenous ligands) |
BAT activation, WAT transdifferentiation |
NPRA agonsit |
BAT, WAT |
|
| Rimonabant |
WAT transdifferentiation |
CB1 antagonist |
WAT, CNS |
Receptor antagonist |
| TZDs, NS-1, balaglitazone, MRL-24, (Sulfonylureas) | WAT (trans-) differentiation, BAT activation | (partial) activation of PPARγ | WAT, BAT | Transcription factor ligand |